Development of the proteasome inhibitor Velcade (Bortezomib). - Wikidata - awgldk - TriplyDB

Development of the proteasome inhibitor Velcade (Bortezomib).

Development of the proteasome inhibitor Velcade (Bortezomib).

http://www.wikidata.org/entity/Q34327233

about

Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?The antitumor natural compound falcarindiol promotes cancer cell death by inducing endoplasmic reticulum stress Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma Cardiovascular autophagy: crossroads of pathology, pharmacology and toxicology Biosensors in clinical practice: focus on oncohematology.Down-regulation of desmosomes in cultured cells: the roles of PKC, microtubules and lysosomal/proteasomal degradation Benzoxaborole as a new chemotype for carbonic anhydrase inhibition Therapeutic targets for the treatment of hepatitis E virus infection Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation Control of Kaposi's sarcoma-associated herpesvirus reactivation induced by multiple signals Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells Qualitative and Quantitative Protein Complex Prediction Through Proteome-Wide Simulations Inflammation meets cancer, with NF-κB as the matchmaker A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.A design principle underlying the paradoxical roles of E3 ubiquitin ligases NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation.Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.Design and synthesis of boronic-acid-labeled thymidine triphosphate for incorporation into DNA.Role of the ubiquitin proteasome system in Alzheimer's disease.Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.Targeting the UPS as therapy in multiple myeloma.Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells Discovery of novel proteasome inhibitors using a high-content cell-based screening system New targets for the treatment of follicular lymphoma.Autophagy contributes to falcarindiol-induced cell death in breast cancer cells with enhanced endoplasmic reticulum stress Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy.Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.Development of HIF-1 inhibitors for cancer therapy Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells Synthesis and inhibition study on tripeptide inhibitor modified poly(L-lysine) dendrimers.Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.

P2860

Q21090814-C686398C-ECB8-4262-B5D8-4B5B2453D678 Q24597424-E8CB8167-987D-4E0F-9331-8B4A19289A40 Q24606479-96F30379-2F52-44AE-B3B6-E5069A19CB5D Q24648025-3FC946A6-E8F4-487C-BEBD-5704F61F13D4 Q26782145-70A9A7F8-8D58-42E5-B5C9-54F883F09833 Q26782159-F2D1C75F-2084-4E86-8B23-ADE97AB2169C Q26858902-FCE30BE2-35AD-4B5F-A667-709F05AD1B5B Q27027114-FDF8B2A4-A65B-4F7F-BB2E-29BF8BED18DA Q27343129-A6E70C5D-8140-4EDE-B7C1-7FA665C12318 Q27728279-79C95915-760D-4660-BEFF-5676D9AB0D41 Q28084036-E4E0B9C1-4165-433C-9FC7-FA5CA415DDB2 Q28475618-1918A4A1-8CCF-4D2C-A544-5C48290B2F94 Q28478842-FCEE473C-8CCB-4EC9-8840-7D968AB695FE Q28481321-078DA115-3DCA-4806-82BD-511C8B0AA943 Q28485441-CF5253D4-CFCD-4870-AFD0-B5868355CBB3 Q28541433-6CDAC28E-093F-463D-B94C-35C2A4C09580 Q28550460-5FA7D991-5DA9-412E-BEFF-EB0734FD89A9 Q29620242-3559204F-213D-47C3-A82A-2958CFE5EEE5 Q30252871-E635A444-B437-4E63-802D-B8C07A5F96DE Q30844250-13545279-E29F-4B1F-90B1-C5CDECB182D3 Q31157266-28C6DCF7-E082-4F83-9C8A-670EF8FEACAC Q33262643-693E010C-C994-4DBF-B96D-24A5C9E520A7 Q33271261-25C14BBD-9799-43B1-B728-E71AC98BCF37 Q33307872-CC83F3B6-BD34-40EE-BCE6-B55F804F7E72 Q33316357-659ACF1B-81A1-4851-8C8B-34624B0F6754 Q33384287-E494FFBB-4AA5-45E5-9C8D-9A048522CB04 Q33442798-7F5A3FC6-1459-4981-B4ED-FC5337E63202 Q33453188-FA1CFFC6-8AF9-4E3A-8B7A-FC3B345CD9B6 Q33521189-12DB48F1-A253-47A3-BEE4-A7B347B807AD Q33587396-7FC9CC80-86CA-4614-A15A-F527EB2D11AC Q33602477-8A71E3AA-4305-4BF5-BAB3-68B942A2893A Q33617012-867891D1-DB43-41C0-8AF0-C81E621105B0 Q33633401-C634B08F-5174-4F46-A525-08253CCB7F2E Q33675494-A2C7EC50-1010-4A48-A26D-00C388D7A6A9 Q33703381-FD6AA59E-25DB-48ED-836D-69F93EB8DDE2 Q33712077-DD1890C0-43F3-4728-99BF-E0FC496101D0 Q33760205-74E61AF3-ED53-4F26-833E-1913D82A19B0 Q33766192-9FD558ED-4BD6-44B8-ADD2-F89B1F5B7591 Q33855223-3A109216-EC35-4B15-B63F-2DFB66CDCECC Q33989444-AEC5FC54-0BF7-414D-85AF-707FBDA5C118

P2860

Development of the proteasome inhibitor Velcade (Bortezomib).

http://www.wikidata.org/entity/Q34327233

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Development of the proteasome inhibitor Velcade (Bortezomib).

@ast

Development of the proteasome inhibitor Velcade (Bortezomib).

@en

Development of the proteasome inhibitor Velcade

@nl

type

label

Development of the proteasome inhibitor Velcade (Bortezomib).

@ast

Development of the proteasome inhibitor Velcade (Bortezomib).

@en

Development of the proteasome inhibitor Velcade

@nl

prefLabel

Development of the proteasome inhibitor Velcade (Bortezomib).

@ast

Development of the proteasome inhibitor Velcade (Bortezomib).

@en

Development of the proteasome inhibitor Velcade

@nl

P1433

Q34327233-5E7774F9-99E4-47AA-BC3B-8FF0E754F5EF

P1476

Q34327233-3D32CF3B-B838-4E44-A238-A361626CD1B8

P2093

Q34327233-732DFD4E-8B9A-4A5A-B496-5D2DE90845AF

Q34327233-BD0706DD-AF76-4C40-BE08-C8B1A7BFB55B

P2860

Q34327233-0B0466EC-5ED3-486D-8F96-3956201C7369

Q34327233-0DBEFE63-EC78-4AD2-B9D3-4DD0520BB5EC

Q34327233-0E6BE470-711D-417A-A002-1AA925D9786C

Q34327233-125FC34D-98B8-46F9-B92A-EB11179ABC66

Q34327233-19A3DD2E-4424-4914-B17B-1C7615C3DF2B

Q34327233-1DA04799-497C-4EBA-9EA1-3B6849F591F3

Q34327233-2F5E02C5-01B4-457D-A6F5-87E72FF4BCE0

Q34327233-3827ED61-9419-4BEE-878A-3C3982F98A77

Q34327233-41D57C7D-645F-4525-8C5C-1F1B23F4F810

Q34327233-532F4640-0444-4611-AF0E-EFC777C633D4

P304

Q34327233-AF772131-DC82-4133-9A75-FEDC03563581

P31

Q34327233-D5264183-A13C-4C32-8763-85A34EBAFE9B

P356

Q34327233-64C96B10-6C48-45C8-9E77-ED6286DC1E2E

P433

Q34327233-2BB28C44-5AC5-44D7-97D5-9181C330F407

P478

Q34327233-75A5E1B3-621C-4D42-8B50-7C83515AF9D3

P577

Q34327233-63C86001-B8F5-46D0-9D3F-7A763F7D5CDF

P698

Q34327233-7C2AD496-5888-4AA7-85AF-6A679F5077B2

P356

P1433

Cancer Investigation

P1476

Development of the proteasome inhibitor Velcade (Bortezomib).

@en

P2093

Julian Adams

http://www.w3.org/2001/XMLSchema#string

Michael Kauffman

http://www.w3.org/2001/XMLSchema#string

P2860

Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP

NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis

The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis

The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

Structure of 20S proteasome from yeast at 2.4 A resolution

How proteolysis drives the cell cycle

Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway

Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination

Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway

P304

304-311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1081/CNV-120030218

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15199612

http://www.w3.org/2001/XMLSchema#string